The Role of Glycocalyx Integrity in the Primary Prevention of Major Cardiovascular Events - Trial NCT04646252
Access comprehensive clinical trial information for NCT04646252 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Athens and is currently Recruiting. The study focuses on Endothelial Dysfunction. Target enrollment is 500 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University of Athens
Timeline & Enrollment
N/A
Jan 10, 2013
Mar 28, 2023
Primary Outcome
Major Adverse Cardiovascular events
Summary
We intend to recruit individuals who are referred for a routine screening in the primary
 prevention outpatient clinic of Attikon University hospital, Athens According to
 institutional protocols, a detailed medical history for atherosclerotic risk factors and
 current medication is recorded and a baseline clinical examination is performed. Moreover
 fasting blood samples are drawn to diagnose the presence of diabetes mellitus and
 hyperlipidemia. Glycocalyx examination is performed at the same visit. The subjects are
 revaluated at one month and then followed up according to the attending physician's
 instructions. All subjects are followed up for adverse events (death, stroke, myocardial
 infarction, hospitalization for heart failure) for 6 years after enrollment via telephonic
 contact and planned appointment at the outpatient clinic.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT04646252
Non-Device Trial